Back to search

Article

Clinical Efficacy of Venetoclax and Azacitidine Treatment for an AML-M5 Patient with Poor Prognosis MDS-EB2 Transformation: A Case Report

2023-05-10

Abstract excerpt

Combination therapy using combination of venetoclax and azacytidine (VEN+AZA) has shown potential in treating acute myeloid leukemia (AML). However, its effectiveness may vary depending on the patient's disease background and genetic mutations. In this case study, we present a patient with M5 type AML who was not a suitable candidate for VEN+AZA treatment. The patient did not respond to the treatment, and the dise...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b3ed6ec5-6fee-5b82-a951-b049f0e6420a
DOI
10.21203/rs.3.rs-2887620/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical Efficacy of Venetoclax and Azacitidine Treatment for an AML-M5 Patient with Poor Prognosis MDS-EB2 Transformation: A Case ReportDOI 10.21203/rs.3.rs-2887620/v1
Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity
Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.Semantic proximity
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity
The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaSemantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity
Select a neighboring publication to make it the new centre.